Table 3.

Serum suPAR in samples from pediatric patient cohorts

DiagnosisSamplessuPAR (pg/ml)
FSGS 28 (26.4)2487 (2191–3351)
Glomerular non-FSGS 25 (22.7)3075 (2532–3465)
 SLE 9 (8.2)3105 (2536–3316)
 MCD 5 (4.5)3075 (2578–4162)
 IgA 3 (2.7)3275 (2930–3365)
 MPGN 3 (2.7)2495 (2187–2828)
 HIV nephropathy 2 (1.8)
 GPA 2 (1.8)
 Membranous 1 (0.9)
Nonglomerular CKD 28 (24.5)3385 (2695–4392)
 Hypo/dysplasia 10 (9.1)3482 (3015–4460)
 Obstructive uropathy 7 (6.4)3575 (2487–4303)
 Other 5 (4.5)
 Unknown 4 (3.6)
 Cortical necrosis 1 (1)
Healthy controls 29 (26.4)2365 (2185–2740)
  • Data are presented as n (%) and median (25%–75% percentile). P>0.05 for all except for nonglomerular CKD versus FSGS, in which P<0.05. suPAR, soluble urokinase receptor; MCD, minimal change disease; MPGN, membranoproliferative GN; GPA, granulomatosis with polyangiitis (Wegener's).